- Home
- VFC vs GH Comparison
VFC vs GH Comparison
Compare VFC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFC
- GH
- Stock Information
- Founded
- VFC 1899
- GH 2011
- Country
- VFC United States
- GH United States
- Employees
- VFC N/A
- GH N/A
- Industry
- VFC Apparel
- GH Medical Specialities
- Sector
- VFC Consumer Discretionary
- GH Health Care
- Exchange
- VFC Nasdaq
- GH Nasdaq
- Market Cap
- VFC 4.9B
- GH 4.9B
- IPO Year
- VFC N/A
- GH 2018
- Fundamental
- Price
- VFC $15.12
- GH $58.80
- Analyst Decision
- VFC Hold
- GH Strong Buy
- Analyst Count
- VFC 18
- GH 17
- Target Price
- VFC $16.56
- GH $58.24
- AVG Volume (30 Days)
- VFC 8.1M
- GH 2.3M
- Earning Date
- VFC 10-27-2025
- GH 11-05-2025
- Dividend Yield
- VFC N/A
- GH N/A
- EPS Growth
- VFC N/A
- GH N/A
- EPS
- VFC N/A
- GH N/A
- Revenue
- VFC $9,496,297,000.00
- GH $828,849,000.00
- Revenue This Year
- VFC $1.66
- GH $28.07
- Revenue Next Year
- VFC $2.86
- GH $21.61
- P/E Ratio
- VFC N/A
- GH N/A
- Revenue Growth
- VFC N/A
- GH 28.74
- 52 Week Low
- VFC $9.41
- GH $20.14
- 52 Week High
- VFC $29.02
- GH $68.00
- Technical
- Relative Strength Index (RSI)
- VFC 60.80
- GH 53.29
- Support Level
- VFC $13.84
- GH $53.40
- Resistance Level
- VFC $15.63
- GH $61.95
- Average True Range (ATR)
- VFC 0.66
- GH 2.54
- MACD
- VFC -0.09
- GH -0.95
- Stochastic Oscillator
- VFC 70.72
- GH 36.99
About VFC V.F. Corporation
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 11 brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.